Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$32.01 USD

32.01
1,959,949

+0.44 (1.39%)

Updated May 31, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Array (ARRY) Submits NDA for Melanoma Combination Therapy

by Zacks Equity Research

Array BioPharma (ARRY) announced that it has submitted two new drug applications (NDAs) to FDA, seeking approval for the combination of binimetinib and encorafenib to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

    Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up

    by Zacks Equity Research

    Celsion Corp. (CLSN) shares rose after the company has announced completion of enrolment in a phase Ib study, evaluating its immunotherapy, GEN-1 in combination with neoadjuvant chemotherapy for treatment of advanced ovarian cancer.

      Roche (RHHBY) Launches Cobas Test for Bacterial Infections

      by Zacks Equity Research

      Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.

        The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

          Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA

          by Zacks Equity Research

          Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar to Roche Holding AG's (RHHBY) Rituxan (rituximab).

            Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

            by Zacks Equity Research

            Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

              Arpita Dutt headshot

              Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises

              by Arpita Dutt

              Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.

                Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe

                by Zacks Equity Research

                Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.

                  Merck's CETP Inhibitor Reduces CV Risk in Phase III Study

                  by Zacks Equity Research

                  Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.

                    Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval

                    by Zacks Equity Research

                    Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.

                      Allergan Continues to Focus on Acquisitions and Branded Unit

                      by Zacks Equity Research

                      We issued an updated research report on Allergan plc (AGN) on Jun 23.

                        Arpita Dutt headshot

                        Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

                        by Arpita Dutt

                        All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

                          Novartis Announces Positive Results for Cardiovascular Drug

                          by Zacks Equity Research

                          Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.

                            Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                            by Zacks Equity Research

                            Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                              Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study

                              by Zacks Equity Research

                              Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.

                                Novartis (NVS) Biosimilar of MabThera Approved in the EU

                                by Zacks Equity Research

                                Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon.

                                  Celgene Presents Interim Results from Cancer Drug Study

                                  by Zacks Equity Research

                                  Celgene Corporation (CELG) announced encouraging results from an interim analysis of a phase IIIb study, MAGNIFY, on Revlimid.

                                    Does Roche Holding (RHHBY) Look to be a Great Value Pick?

                                    by Zacks Equity Research

                                    Roche Holding is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                                      J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

                                      by Zacks Equity Research

                                      Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

                                        Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year

                                        by Zacks Equity Research

                                        Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.

                                          Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval

                                          by Zacks Equity Research

                                          Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.

                                            Why is Alnylam's (ALNY) Stock Close to 100% this Year?

                                            by Zacks Equity Research

                                            Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.

                                              Epizyme Provides Positive Interim Data on EZH2 Inhibitor

                                              by Zacks Equity Research

                                              Epizyme, Inc. (EPZM) announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat as a monotherapy in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma

                                                Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

                                                by Zacks Equity Research

                                                Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

                                                  Why is Kite Pharma (KITE) Stock Up Close to 100% this Year?

                                                  by Zacks Equity Research

                                                  Shares of Kite Pharma, Inc. (KITE) were up around 5.6% on Thursday.